A New Cancer Testis Antigen Linked to Diffuse Large B-Cell Lymphoma
Author Information
Author(s): Liggins A P, Brown P J, Asker K, Pulford K, Banham A H
Primary Institution: Nuffield Department of Clinical Laboratory Sciences, University of Oxford
Hypothesis
Can the identification of a novel cancer testis antigen improve the understanding and treatment of diffuse large B-cell lymphoma?
Conclusion
The study identifies PASD1 as a novel cancer testis antigen that is expressed in diffuse large B-cell lymphoma and may serve as a potential target for immunotherapy.
Supporting Evidence
- PASD1 was recognized by serum from four out of ten patients with DLBCL.
- Expression studies indicated that PASD1 is widely expressed in solid tumors and DLBCL-derived cell lines.
- PASD1 expression was found in histologically normal tissues from cancer patients.
Takeaway
Researchers found a new protein that could help the immune system fight a type of blood cancer called diffuse large B-cell lymphoma.
Methodology
The study used SEREX to identify proteins expressed in DLBCL and confirmed the expression of PASD1 in various cell lines and patient samples.
Limitations
The study's findings are based on a limited number of patient samples and may not be generalizable to all DLBCL cases.
Participant Demographics
Patients with diffuse large B-cell lymphoma, including those with de novo and transformed cases.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website